MULTIPLE SCLEROSIS SØGNING UDFØRT 27. MAJ 2013... · MAJ 2013 v/ søgekonsulent Kirsten Birkefoss, [email protected] Kontaktperson: Birgitte Holm Petersen, [email protected] ... 31 October

1

MULTIPLE SCLEROSIS SØGNING UDFØRT 27. MAJ 2013

v/ søgekonsulent Kirsten Birkefoss, [email protected]

Kontaktperson: Birgitte Holm Petersen, [email protected]

Klik på titlen, der linker til de enkelte guidelines (undtagen HTA Database) Der er søgt i:

GIN (International)

NICE (UK) National Guideline Clearinghouse (USA) SIGN (Skotland)

HTA Database (UK) Cochrane

SBU (Sverige) Socialstyrelsen (Sverige) Kunnskapssenteret (Norge)

Helsedirektoratet (Norge) Helsebiblioteket (Norge)

Pedro OTSeeker National Health and Medical Research Council (Australia)

PubMed Cinahl

Der er kun brugt tidsafgrænsningen, 2003-2013 I databaserne Pubmed og Cinahl.

GIN (password restricted) Søgt på: multiple sclerosis (engelsk, dansk, svensk norsk)

4 fund, som også er fundet i NICE og SBU (se fund i disse databaser

nedenfor)

NICE (UK)

Søgt på: multiple sclerosis (guideline)

11 fund 1)

Multiple sclerosis (CG8)

The summary of the published clinical guideline on Multiple sclerosis. It links to the published

guidance and key documents.

mailto:[email protected]:[email protected]://www.nice.org.uk/_gs/searchtracker/GUIDANCE/10930

2

View the summary and implementation tools 01 November 2003

o Full Guidance o NICE Guidance

o Information for the public

Multiple sclerosis

Multiple sclerosis Multiple sclerosis (MS) is a disease of the central nervous system (brain and

spinal cord). The disease process is one of episodes where white matter within the brain or spinal cord

becomes inflamed and then destroyed by the person's own

Appendix F: Diagnosis of multiple sclerosis

Appendix F: Diagnosis of multiple sclerosis The full guideline contains this information.

Rapid diagnosis

Rapid diagnosis An individual who is suspected of having multiple sclerosis should be referred to a

specialist neurology service, and seen rapidly within an audited time. The individual should be seen

again after all investigations necessary to confirm

2)

Multiple sclerosis (2014)

Management of multiple sclerosis in primary and secondary care

Status: Referred

Publication date: TBC

Wave: R

Process: CG

Topic area:

Central nervous system

Project team | Schedule | Project history | Key documents

NICE project team

Centre for clinical practice lead: Christine Carson

Communications manager: Paul Cooney

Guidelines commissioning manager: Caroline Keir

Guidelines coordinator: Margaret Ghlaimi

Patient involvement lead: Barbara Meredith

http://guidance.nice.org.uk/CG8http://guidance.nice.org.uk/CG8/Guidance/pdf/Englishhttp://guidance.nice.org.uk/CG8/NICEGuidance/pdf/Englishhttp://guidance.nice.org.uk/CG8/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/CG8/PublicInfo/pdf/Englishhttp://publications.nice.org.uk/multiple-sclerosis-cg8/multiple-sclerosishttp://publications.nice.org.uk/multiple-sclerosis-cg8/appendix-f-diagnosis-of-multiple-sclerosishttp://publications.nice.org.uk/multiple-sclerosis-cg8/key-priorities-for-implementation#rapid-diagnosishttp://guidance.nice.org.uk/CG/WaveR/115#projectTeamhttp://guidance.nice.org.uk/CG/WaveR/115#schedulehttp://guidance.nice.org.uk/CG/WaveR/115#historyhttp://guidance.nice.org.uk/CG/WaveR/115#keydocs

3

Implementation lead: TBC

Guidelines Development Group: The Guideline Development Group (GDG) oversees the development process.

Email enquiriesIf you have any queries please email [email protected]

Provisional schedule

Scoping workshop: 05 April 2012

Consultation on draft scope with stakeholders: 8 May - 7 June 2012

Consultation on draft guideline with stakeholders: TBC

Publication date: TBC

Project history

Date Update

3 August 2012

The scope defines what aspects of care are covered by the guideline and to whom it applies. Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table. The Guideline Development Group (GDG) oversees the development process.

8 May 2012

The draft scope is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed, by the deadline shown.

31 October 2011

The first draft of the scope is currently in preparation. The scope will define what aspects of care the guideline will cover and to whom it will apply.

Top

Top

mailto:[email protected]://guidance.nice.org.uk/_gs/link/?id=1717E5BD-19B9-E0B5-D4E01089A7EDB94Bhttp://guidance.nice.org.uk/CG/WaveR/115#pagetophttp://guidance.nice.org.uk/CG/WaveR/115#pagetop

4

Key documents

Multiple sclerosis (2014): scoping workshop, consultation and final scope 29 August 2012

Multiple Sclerosis (2014): guideline development and consultation 03 August 2012

Multiple sclerosis (2014): list of stakeholders and how to register 16 May 2012

Multiple sclerosis (2014): stakeholder list 08 May 2012

Multiple Sclerosis (update): NCC information 31 October 2011

Multiple Sclerosis (update): The Guideline Development Process - an overview for stakeholders, the public and the NHS

31 October 2011

This page was last updated: 24 May 2013

3) Multiple sclerosis - natalizumab (TA127) The summary of the published technology appraisal on Multiple sclerosis - natalizumab. It links to the published guidance and key documents. View the summary and implementation tools22 August 2007 Full Guidance Quick reference guide

Information for the public

4) Guidance issued Multiple sclerosis (CG8) The summary of the published clinical guideline on Multiple sclerosis. It links to the published guidance and key documents. View the summary and implementation tools01 November 2003 Full Guidance NICE Guidance


5) Guidance issuedMultiple sclerosis (relapsing-remitting) - fingolimod (TA254) The summary of the published technology appraisal on Multiple sclerosis (relapsing-remitting) - fingolimod. It links to the published guidance and key documents. View the summary and implementation tools25 April 2012 Full Guidance


Top

http://guidance.nice.org.uk/CG/WaveR/115/Scopinghttp://guidance.nice.org.uk/CG/WaveR/115/Developmenthttp://guidance.nice.org.uk/guidance/index.jsp?action=folder&o=59243http://guidance.nice.org.uk/CG/WaveR/115/SHList/pdf/Englishhttp://guidance.nice.org.uk/_gs/link/?id=59E25114-19B9-E0B5-D4894577AB2795FDhttp://guidance.nice.org.uk/_gs/link/?id=59E00F28-19B9-E0B5-D4B352883C38FAD8http://guidance.nice.org.uk/_gs/link/?id=59E00F28-19B9-E0B5-D4B352883C38FAD8http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11822http://guidance.nice.org.uk/TA127http://guidance.nice.org.uk/TA127/Guidance/pdf/Englishhttp://guidance.nice.org.uk/TA127/QuickRefGuide/pdf/Englishhttp://guidance.nice.org.uk/TA127/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/TA127/PublicInfo/pdf/Englishhttp://www.nice.org.uk/_gs/searchtracker/GUIDANCE/10930http://guidance.nice.org.uk/CG8http://guidance.nice.org.uk/CG8/Guidance/pdf/Englishhttp://guidance.nice.org.uk/CG8/NICEGuidance/pdf/Englishhttp://guidance.nice.org.uk/CG8/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/CG8/PublicInfo/pdf/Englishhttp://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13719http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13719http://guidance.nice.org.uk/TA254http://guidance.nice.org.uk/TA254/Guidance/pdf/Englishhttp://guidance.nice.org.uk/TA254/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/TA254/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/CG/WaveR/115#pagetop

5

6) Guidance issuedPercutaneous venoplasty for chronic cerebrospinal venous insufficiency for multiple sclerosis (IPG420) The summary of the published interventional procedure on Percutaneous venoplasty for chronic cerebrospinal venous insufficiency for multiple sclerosis. It links to the published guidance and key documents. View the summary and implementation tools28 March 2012 Full Guidance


7) Guidance issuedMultiple sclerosis - beta interferon and glatiramer acetate (TA32) The summary of the published technology appraisal on Multiple sclerosis - beta interferon and glatiramer acetate. It links to the published guidance and key documents. View the summary and implementation tools01 January 2002 Full Guidance

8) SuspendedMultiple sclerosis - cladribine [ID64] The summary of the suspended technology appraisal on Multiple sclerosis - cladribine [ID64]. It links to the suspended guidance and key documents.

9) DiscontinuedMultiple sclerosis - sativex [ID387] The summary of the discontinued technology appraisal on Multiple sclerosis - sativex [ID387]. It links to the discontinued guidance and key documents.

10) In progressMultiple sclerosis (primary-progressive) - fingolimod [ID62] The summary of the in development technology appraisal on Multiple sclerosis (primary-progressive) - fingolimod [ID62]. It links to the key documents, details of NICE staff and external stakeholders involved in developing NICE guidance.

11) In progressMultiple sclerosis (relapsing-remitting) - laquinimod [ID560] The summary of the in development technology appraisal on Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]. It links to the key documents, details of NICE staff and external stakeholders involved in developing NICE guidance.

http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13064http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13064http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13064http://guidance.nice.org.uk/IPG420http://guidance.nice.org.uk/IPG420/Guidance/pdf/Englishhttp://guidance.nice.org.uk/IPG420/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/IPG420/PublicInfo/pdf/Englishhttp://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11441http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11441http://guidance.nice.org.uk/TA32http://guidance.nice.org.uk/TA32/Guidance/pdf/Englishhttp://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11896http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11681http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/12171http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/12171http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/14058http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/14058

6

National Guideline Clearinghouse (USA)

1-20 of 58 Next >

1. Comparison of Multiple Sclerosis Guidelines Underscores Need for Collaboration

Compare Selected

2. Fingolimod for the treatment of highly active relapsing-

remitting multiple sclerosis. 2012 Apr. NGC:009075 National Institute for Health and Care Excellence (NICE) -

National Government Agency [Non-U.S.]. View all guidelines by the developer(s)

Compare

Selected

3. Evidence report: the efficacy and safety of mitoxantrone

(Novantrone) in the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment

Subcommittee of the American Academy of Neurology. 2003 Nov 25 (revised 2010 May). NGC:008150

American Academy of Neurology - Medical Specialty Society. View all guidelines by the developer(s)

Compare

Selected

4. Nursing management of the patient with multiple sclerosis. 2011. NGC:009286

American Association of Neuroscience Nurses - Professional Association; Association of Rehabilitation Nurses - Professional

Association; International Organization of Multiple Sclerosis Nurses - Professional Association. View all guidelines by the

developer(s)

Compare Selected

5. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based

review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of

Neurology. 2008 Sep 2. NGC:006705 American Academy of Neurology - Medical Specialty Society.

View all guidelines by the developer(s)

Compare Selected

6. Use of imaging in multiple sclerosis. 2006 Apr (revised

2011). NGC:008784 European Federation of Neurological Societies - Medical

Specialty Society. View all guidelines by the developer(s)

Compare

Selected

7. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment

Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology

Society. 2003 Sep 9 (reaffirmed 2008 Nov 15). NGC:003154

Compare Selected

javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl01$lbNext','')http://guideline.gov/expert/expert-commentary.aspx?id=16443&search=multiple+sclerosishttp://guideline.gov/expert/expert-commentary.aspx?id=16443&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36885&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36885&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1178http://guideline.gov/browse/by-organization.aspx?orgid=1178http://guideline.gov/content.aspx?id=24497&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24497&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24497&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24497&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=38259&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38259&search=multiple+sclerosisjavascript:LaunchDevs('38259');javascript:LaunchDevs('38259');http://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=34911&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=4109&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4109&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4109&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4109&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4109&search=multiple+sclerosis

7

American Academy of Neurology - Medical Specialty Society; Child Neurology Society - Medical Specialty Society. View all

guidelines by the developer(s)

8. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment

Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. 2002

Jan 22 (reaffirmed 2008 Jul 19). NGC:003144

American Academy of Neurology - Medical Specialty Society; Multiple Sclerosis Council - Disease Specific Society. View all

guidelines by the developer(s)

Compare Selected

9. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and

Technology Assessment Subcommittee of the American Academy of Neurology. 1996 (revised 2011 Jan 18).

NGC:008274 American Academy of Neurology - Medical Specialty Society.


Compare Selected

10. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases.

2008 Sep. NGC:006937 European Federation of Neurological Societies - Medical


Compare Selected

11. Dementia in the long-term care setting. 1998 (revised

2009). [NGC Update Pending] NGC:007639 American Medical Directors Association - Professional

Association. View all guidelines by the developer(s)

Compare

Selected

12. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. 2006 Nov (revised 2010

Sep). NGC:008162 European Federation of Neurological Societies - Medical


Compare Selected

13. Urinary incontinence in neurological disease. Management of lower urinary tract dysfunction in

neurological disease. 2012 Aug. NGC:009310 National Clinical Guideline Centre - National Government

Agency [Non-U.S.]. View all guidelines by the developer(s)

Compare Selected

14. Guidelines of care for the management of psoriasis and

psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with

biologics. 2008 May. NGC:006435 American Academy of Dermatology - Medical Specialty

Society. View all guidelines by the developer(s)

Compare

Selected

15. ACR Appropriateness Criteria® cranial neuropathy. Compare

javascript:LaunchDevs('4109');javascript:LaunchDevs('4109');http://guideline.gov/content.aspx?id=4099&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4099&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4099&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4099&search=multiple+sclerosisjavascript:LaunchDevs('4099');javascript:LaunchDevs('4099');http://guideline.gov/content.aspx?id=25656&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=25656&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=25656&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=25656&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=13565&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13565&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=15594&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=771http://guideline.gov/content.aspx?id=24525&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24525&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=38411&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38411&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38411&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=2317http://guideline.gov/content.aspx?id=12505&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12505&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12505&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12505&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=36http://guideline.gov/content.aspx?id=37947&search=multiple+sclerosis

8

2009 (revised 2012). NGC:009252 American College of Radiology - Medical Specialty Society.


Selected

16. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis. Report of the

Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

2011 Dec 13. NGC:008839


Compare Selected

17. Ulcerative colitis practice guidelines in adults:

American College of Gastroenterology, Practice Parameters Committee. 2010 Mar. NGC:009292

American College of Gastroenterology - Medical Specialty Society. View all guidelines by the developer(s)

Compare

Selected

18. Nystagmus and oscillopsia. 2004 Feb (revised 2012 Jan).

NGC:009361 European Federation of Neurological Societies - Medical


Compare

Selected

19. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the

treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

2011 Jul. NGC:009039

American Academy of Dermatology - Medical Specialty Society. View all guidelines by the developer(s)

Compare Selected

20. BSR and BHPR rheumatoid arthritis guidelines on

safety of anti-TNF therapies. 2001 (revised 2010). NGC:009434

British Health Professionals in Rheumatology - Professional Association; British Society for Rheumatology - Medical


Compare

Selected

1-20 of 58 Next >

21-40 of 58 < Previous | Next >

21. Guidelines on neurogenic lower urinary tract

dysfunction. 2003 (revised 2011 Mar). NGC:008601 European Association of Urology - Medical Specialty Society.


Compare

Selected

22. Palliative care. 2007 Jan (revised 2011 Nov). NGC:008961 Institute for Clinical Systems Improvement - Nonprofit

Organization. View all guidelines by the developer(s)

Compare Selected

http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=35116&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=35116&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=35116&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=35116&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=38323&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38323&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38323&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=588http://guideline.gov/content.aspx?id=38472&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=36824&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36824&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36824&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36824&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=36http://guideline.gov/content.aspx?id=38656&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38656&search=multiple+sclerosisjavascript:LaunchDevs('38656');javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl24$lbNext','')javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl01$lbPrev','')javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl01$lbNext','')http://guideline.gov/content.aspx?id=34062&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=34062&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=2034http://guideline.gov/content.aspx?id=36058&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722

9

23. Screening and Risk Assessment for Osteoporosis

Compare Selected

24. ACR Appropriateness Criteria® ataxia. 1999 (revised

2012). NGC:009237 American College of Radiology - Medical Specialty Society.


Compare

Selected

25. ACR Appropriateness Criteria® focal neurologic deficit. 2006 (revised 2012). NGC:009223

American College of Radiology - Medical Specialty Society.


Compare Selected

26. Chronic fatigue syndrome/myalgic encephalomyelitis. A primer for clinical practitioners. 2012. NGC:009288

International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis - Nonprofit


Compare Selected

27. Hip and groin disorders. 2011. NGC:009298 American College of Occupational and Environmental

Medicine - Medical Specialty Society. View all guidelines by the developer(s)

Compare Selected

28. ACR Appropriateness Criteria® orbits, vision and visual

loss. 1999 (revised 2012). NGC:009239 American College of Radiology - Medical Specialty Society.


Compare

Selected

29. Routine cerebrospinal fluid (CSF) analysis. 2006 Sep

(revised 2011). NGC:008781 European Federation of Neurological Societies - Medical


Compare

Selected

30. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from

the American College of Physicians. 2009 Nov 3. NGC:007688

American College of Physicians - Medical Specialty Society. View all guidelines by the developer(s)

Compare Selected

31. Evidence-based guideline: intravenous immunoglobulin

in the treatment of neuromuscular disorders. Report of the Therapeutics and Technology Assessment

Subcommittee of the American Academy of Neurology. 2012 Mar 27. NGC:009085

American Academy of Neurology - Medical Specialty Society.


Compare

Selected

32. ACR Appropriateness Criteria® cerebrovascular disease. 1996 (revised 2011). NGC:008482

American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)

Compare Selected

http://guideline.gov/syntheses/synthesis.aspx?id=38658&search=multiple+sclerosishttp://guideline.gov/syntheses/synthesis.aspx?id=38658&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=37932&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=37918&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=38316&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38316&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=2350http://guideline.gov/content.aspx?id=38357&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=446http://guideline.gov/browse/by-organization.aspx?orgid=446http://guideline.gov/content.aspx?id=37934&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=37934&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=34908&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=15652&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15652&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15652&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=140http://guideline.gov/content.aspx?id=36895&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36895&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36895&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36895&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=32645&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=32645&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246

10

33. Occupational therapy practice guidelines for adults with traumatic brain injury. 2009. NGC:007509

American Occupational Therapy Association, Inc. - Professional Association. View all guidelines by the

developer(s)

Compare Selected

34. Risk factor assessment for osteoporosis and/or increased fracture risk in men. 2008 May. NGC:006587

University of Texas at Austin School of Nursing, Family Nurse

Practitioner Program - Academic Institution. View all guidelines by the developer(s)

Compare Selected

35. Assessment: botulinum neurotoxin in the treatment of

autonomic disorders and pain (an evidence-based review). Report of the Therapeutics and Technology

Assessment Subcommittee of the American Academy of Neurology. 2008 May 6. NGC:006658


Compare

Selected

36. Pressure ulcer prevention and treatment protocol.

Health care protocol. 2008 Jan (revised 2012 Jan). NGC:008962

Institute for Clinical Systems Improvement - Nonprofit Organization. View all guidelines by the developer(s)

Compare

Selected

37. Association for the Advancement of Wound Care

guideline of pressure ulcer guidelines. 2010 Oct 1.

NGC:008120 Association for the Advancement of Wound Care - Nonprofit


Compare

Selected

38. Major depression in adults in primary care. 1996 Jan (revised 2012 May). NGC:009117

Institute for Clinical Systems Improvement - Nonprofit Organization. View all guidelines by the developer(s)

Compare Selected

39. VA/DoD clinical practice guideline for management of

major depressive disorder (MDD). 1997 (revised 2009 May). NGC:007711

Department of Defense - Federal Government Agency [U.S.]; Department of Veterans Affairs - Federal Government Agency

[U.S.]; Veterans Health Administration - Federal Government Agency [U.S.]. View all guidelines by the developer(s)

Compare

Selected

40. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based

review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

and the European Federation of Neurological Societies. 2008 Oct 7. NGC:006700

American Academy of Neurology - Medical Specialty Society;

Compare Selected

http://guideline.gov/content.aspx?id=15287&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15287&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=165http://guideline.gov/browse/by-organization.aspx?orgid=165http://guideline.gov/content.aspx?id=12785&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12785&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1096http://guideline.gov/browse/by-organization.aspx?orgid=1096http://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=36059&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36059&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722http://guideline.gov/content.aspx?id=24361&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24361&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1736http://guideline.gov/content.aspx?id=37277&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722http://guideline.gov/content.aspx?id=15675&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15675&search=multiple+sclerosisjavascript:LaunchDevs('15675');http://guideline.gov/content.aspx?id=13006&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13006&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13006&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13006&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13006&search=multiple+sclerosis

11

European Federation of Neurological Societies - Medical Specialty Society. View all guidelines by the developer(s)

21-40 of 58 < Previous | Next >

41-58 of 58 < Previous

41. Urinary incontinence in women. 2001 Jan 4 (revised 2008 Aug 8). NGC:006743

Finnish Medical Society Duodecim - Professional Association. View all guidelines by the developer(s)

Compare Selected

42. ACR Appropriateness Criteria® vertigo and hearing loss. 1996 (revised 2008). NGC:007784


Compare Selected

43. Screening for hearing loss in older adults: U.S.

Preventive Services Task Force recommendation statement. 1996 (revised 2012 Nov 6). NGC:009297

U.S. Preventive Services Task Force - Independent Expert Panel. View all guidelines by the developer(s)

Compare

Selected

44. Assessment and management of chronic pain. 2005 Nov

(revised 2011 Nov). NGC:008967 Institute for Clinical Systems Improvement - Nonprofit


Compare

Selected

45. Practice parameters for the surgical modifications of the upper airway for obstructive sleep apnea in adults. 1996

Feb (revised 2010 Oct). NGC:008113

American Academy of Sleep Medicine - Professional Association. View all guidelines by the developer(s)

Compare Selected

46. Best evidence statement (BESt). Wheelchair delivery

evaluation. 2010 Nov. NGC:008529 Cincinnati Children's Hospital Medical Center - Hospital/Medical

Center. View all guidelines by the developer(s)

Compare

Selected

47. Sleep disorders in neurodegenerative disorders and stroke. 2007 Nov (revised 2011). NGC:008782

European Federation of Neurological Societies - Medical Specialty Society. View all guidelines by the developer(s)

Compare Selected

48. ACR Appropriateness Criteria® dementia and movement

disorders. 1996 (revised 2010). NGC:008455 American College of Radiology - Medical Specialty Society. View

all guidelines by the developer(s)

Compare

Selected

49. Lymphoma. 2012 Sep. NGC:009392

Alberta Health Services, Cancer Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)

Compare

Selected

javascript:LaunchDevs('13006');javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl24$lbPrev','')javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl24$lbNext','')javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl01$lbPrev','')http://guideline.gov/content.aspx?id=13195&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1110http://guideline.gov/content.aspx?id=15749&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=38356&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38356&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38356&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=345http://guideline.gov/content.aspx?id=36064&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722http://guideline.gov/content.aspx?id=24178&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24178&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=105http://guideline.gov/content.aspx?id=33282&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=33282&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=925http://guideline.gov/content.aspx?id=34909&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=34909&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=32612&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=32612&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=38593&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=2278

12

50. American College of Rheumatology guidelines for screening, treatment, and management of lupus

nephritis. 2012 Jun. NGC:009090 American College of Rheumatology - Medical Specialty Society.


Compare Selected

51. Immunizations. 2007 Oct (revised 2012 Mar). NGC:009028 Institute for Clinical Systems Improvement - Nonprofit


Compare Selected

52. Oral hygiene care for functionally dependent and

cognitively impaired older adults. 2002 Nov (revised 2011

Jul). NGC:008700 University of Iowa College of Nursing, John A. Hartford

Foundation Center of Geriatric Nursing Excellence - Academic Institution. View all guidelines by the developer(s)

Compare

Selected

53. ACR Appropriateness Criteria® Hodgkin's lymphoma—

favorable prognosis stage I and II. 1999 (revised 2011). NGC:008470


Compare

Selected

54. ACR Appropriateness Criteria® seizures and epilepsy.

1996 (revised 2011). NGC:008451 American College of Radiology - Medical Specialty Society. View


Compare

Selected

55. ACR Appropriateness Criteria® dysphagia. 1998 (revised

2010). NGC:007921 American College of Radiology - Medical Specialty Society. View


Compare

Selected

56. ACR Appropriateness Criteria® limping child — ages 0-5 years. 1995 (revised 2012). NGC:009219


Compare Selected

57. Practice parameter update: the care of the patient with

amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Report

of the Quality Standards Subcommittee of the American Academy of Neurology. 1999 Apr (revised 2009 Oct 13).

NGC:007839 American Academy of Neurology - Medical Specialty Society.


Compare

Selected

58. Practice parameter update: the care of the patient with

amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral

impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American

Compare

Selected

http://guideline.gov/content.aspx?id=36900&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36900&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36900&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=586http://guideline.gov/content.aspx?id=36813&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722http://guideline.gov/content.aspx?id=34447&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=34447&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=930http://guideline.gov/content.aspx?id=32633&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=32633&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=32608&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=23815&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=37914&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=37914&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15954&search=multiple+sclerosis

13

Academy of Neurology. 1999 Apr (revised 2009 Oct 13). NGC:007840


41-58 of 58 < Previous

SIGN (Skotland)

0 fund

HTA Database (The University of York, Centre for Reviews and

Dissemination) Søgt på: multiple sclerosis

66 fund

Results for: (multiple sclerosis):TI IN HTA

1 2012

HTA NIHR Horizon Scanning

Centre (NIHR HSC) BIIB-017

for relapsing

forms of

multiple

sclerosis [Preview]

2 2012 HTA Catalan Agency for

Health

Information,

Assessment

[Clinical practice

guideline of care for

people with multiple

sclerosis] [Preview]

http://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl22$lbPrev','')

14

and Quality

(CAHIAQ -

formerly

CAHTA)

3 2012 HTA L'Institut national

d'excellence

en sante et en

services

sociaux

(INESSS)

Diagnosis and

treatment of chronic

cerebrospinal

venous insufficiency

(CCSVI) for people

with multiple

sclerosis [Preview]

4 2012 HTA L'Institut national

d'excellence

en sante et en

services

sociaux

(INESSS)

[Diagnosis and

treatment of Chronic

Cerebrospinal

Venous

Insufficiency

(CCSVI) in people

with Multiple

Sclerosis (MS)] [Preview]

5 2012 HTA Canadian Agency for

Drugs and

Technologies

in Health

(CADTH)

Modafinil for sleep

disorders and

fatigue secondary to

multiple sclerosis: a

review of the

clinical efficacy and

safety [Preview]

6 2011 HTA Institute for Clinical

Effectiveness

and Health

Policy (IECS)

[Dalfampridine

(ampyra) in multiple

sclerosis patients] [Preview]

7 2011 HTA National Horizon

Scanning

Centre

(NHSC)

Dimethyl fumarate

for relapsing-

remitting multiple

sclerosis [Preview]

8 2011 HTA HAYES, Inc. Functional Electrical Stimulation (FES)

for treatment of foot

drop in multiple

15

sclerosis patients [Preview]


Scanning

Centre

(NHSC)

Laquinimod for

multiple sclerosis:

relapsing-remitting -

first or second line. [Preview]

10 2011 HTA HAYES, Inc. Neutralizing Antibody (NAb)

testing using the

myxovirus protein A

(MxA) assay to

assess interferon

beta treatment of

multiple sclerosis [Preview]


Scanning

Centre

(NHSC)

Teriflunomide for

relapsing multiple

sclerosis (MS) - first

line [Preview]


Scanning

Centre

(NHSC)

Fampridine-PR for

multiple sclerosis:

impaired mobility -

first line [Preview]

13 2010 HTA HAYES, Inc. High-dose immunosuppressive

therapy with or

without

hematopoietic

transplantation for

the treatment of


14 2010 HTA HAYES, Inc. Neutralizing antibody (NAb)

testing using the

cytopathic effect

(CPE) assay to

16

assess interferon

beta treatment of


15 2010 HTA HAYES, Inc. Rituxan (Rituximab) (Genentech Inc. and

Biogen Idec Inc.)

for multiple

sclerosis [Preview]

16 2009 HTA NIHR Health Technology

Assessment

programme

Improving the

evaluation of

therapeutic

interventions in

multiple sclerosis:

the role of new

psychometric

methods [Preview]

17 2009 HTA HAYES, Inc. Natalizumab (Tysabri, Biogen

Idec and Elan

Pharmaceuticals) for

relapsing remitting



Scanning

Centre

(NHSC)

Sativex for

spasticity in



Scanning

Centre

(NHSC)

Cladribine

(Movectro) for

multiple sclerosis;

relapsing-remitting [Preview]


Scanning

Centre

(NHSC)

Dirucotide for

secondary

progressive multiple

sclerosis [Preview]

17

21 2008 HTA German Agency for

Health

Technology

Assessment at

the German

Institute for

Medical

Documentation

and

Information

(DAHTA@

DIMDI)

[Interferons

and

natalizumab

for multiple

sclerosis] [Preview]

22

2008 HTA Institute for Clinical

Effectiveness

and Health

Policy (IECS)

T-cell vaccines for

the treatment of


23

2007 HTA HAYES, Inc. 3.0 Tesla (3T) Magnetic

Resonance Imaging

(MRI) for multiple

sclerosis [Preview]

24

2007 HTA National Institute for

Health and

Clinical

Excellence

(NICE)

Natalizumab for the

treatment of adults

with highly active

relapsing-remitting


25

2006 HTA VA Technology

Assessment

Program

(VATAP)

Bone marrow

transplantation for

treatment of


26

2006 HTA HAYES, Inc. Deep brain stimulation for

treatment of

movement

disorders of


18

27

2006 HTA HAYES, Inc. Plasma exchange for multiple

sclerosis [Preview]

28

2006 HTA Technology Assessment

Unit of the

McGill

University

Health Centre

(MUHC)

The use of

mitoxantrone in the

treatment of

patients with

multiple sclerosis:

report update [Preview]

29

2006 HTA HAYES, Inc. Visual evoked potentials in the

diagnosis/prognosis

of multiple

sclerosis [Preview]

30

2005 HTA HAYES, Inc. Intrathecal baclofen for spasticity of

spinal origin or due

to multiple

sclerosis [Preview]

31

2005 HTA HAYES, Inc. Intravenous immunoglobulin

for multiple

sclerosis [Preview]

32

2005 HTA Canadian Coordinating

Office for

Health

Technology

Assessment

(CCOHTA)

Sativex for the

management of

multiple sclerosis

symptoms [Preview]

33

2004 HTA University HealthSystem

Consortium

(UHC)

Agents for multiple

sclerosis (TCR) [Preview]

34

2004 HTA Agency for Healthcare

Criteria to

determine disability

19

Research and

Quality

(AHRQ)

related to multiple

sclerosis [Preview]

35

2004 HTA NIHR Health Technology

Assessment

programme

Improving the

evaluation of

therapeutic

interventions in

multiple sclerosis:

development of a

patient-based

measure of

outcome [Preview]

36

2004 HTA HAYES, Inc. Interferon beta for multiple sclerosis [Preview]

37


Assessment

programme

Methods for

expected value of

information

analysis in complex

health economic

models:

developments on

the health

economics of

interferon-beta and

glatiramer acetate

for multiple

sclerosis [Preview]

38

2003 HTA National Institute for

Clinical

Excellence

(NICE)

Multiple sclerosis:

management of

multiple sclerosis

in primary and

secondary care [Preview]

39


Assessment

programme

Treatments for

spasticity and pain

in multiple

sclerosis: a

systematic review [Preview]

20

40


Assessment

programme

A review of the

natural history and

epidemiology of

multiple sclerosis:

implications for

resource allocation

and health

economic models [Preview]

41

2002 HTA National Institute for Clinical

Excellence

(NICE)

Guidance on the use of beta

interferon and glatiramer acetate

for the treatment of multiple

sclerosis [Preview]

42

2002 HTA Bazian Ltd, Wessex Institute

for Health

Research and

Development

(WIHRD)

Hyperbaric oxygen therapy for


43

2002 HTA ECRI Interferon beta [IFNb] -1a and -1b for treatment of relapsing-

remitting multiple sclerosis [Preview]

44

2002 HTA National Horizon Scanning Centre

(NHSC)

Mitoxantrone for multiple

sclerosis - horizon scanning

review [Preview]

45

2002 HTA National Horizon Scanning Centre

(NHSC)

Natalizumab for multiple

sclerosis - horizon scanning

review [Preview]

46

2002 HTA Technology Assessment Unit

of the McGill

University Health

Centre (MUHC)

Should the McGill University

Health Center use mitoxantrone

in the treatment of multiple

sclerosis? [Preview]

47

2001 HTA Institute for Clinical Systems

Interferon beta-1a, interferon

beta-1b, glatiramer acetate, and

21

Improvement

(ICSI) mitoxantrone (for treatment of

multiple sclerosis) [Preview]

48

HTA ECRI Plasmapheresis for the treatment of multiple sclerosis [Preview]

49


Assessment

programme

The role of the specialist nurse in

multiple sclerosis: a rapid and


50


Assessment

programme

Disease-modifying drugs for



51


Assessment

programme

Treatments for fatigue in



52 1999 HTA Wessex Institute

for Health

Research and

Development

(WIHRD)

Beta intererons (1a and 1b) in

elapsing-remitting and secondary

progressive multiple sclerosis [Preview]

53 1999 HTA Danish Centre for

Evaluation and

Health

Technology

Assessment

(DACEHTA)

[Beta-interferon treatment in

RRMS and secondary

progressive multiple sclerosis] [Preview]

54 1999 HTA NIHR Health

Technology

Assessment

programme

Development of the protocol for

the proposed trial of beta

interferon in multiple sclerosis [Preview]

55 1999 HTA Danish Centre for

Evaluation and

Health

Technology

Assessment

(DACEHTA)

Interferon beta treatment for

multiple sclerosis (funded by

DIHTA) [Preview]

56 1998 HTA NIHR Health A cost-utility analysis of

22

Technology

Assessment

programme

interferon beta for multiple

sclerosis [Preview]

57 1998 HTA Canadian

Coordinating

Office for Health

Technology

Assessment

(CCOHTA)

Comparison of drug treatments

for multiple sclerosis - systematic

review [Preview]

58 1998 HTA NIHR Health

Technology

Assessment

programme

Cost-effectiveness of interferon

beta for multiple sclerosis: the

implications of new information

on clinical effectiveness [Preview]

59 1997 HTA Wessex Institute

for Health

Research and

Development

(WIHRD)

Interferon beta-1a in relapsing-


60 1996 HTA Canadian

Coordinating

Office for

Health

Technology

Assessment

(CCOHTA)

A therapeutic and economic

assessment of Betaseron in

multiple sclerosis - systematic

review [Preview]

1996

61

HTA Wessex Institute for

Health

Research and

Development

(WIHRD)

Copolymer 1 in relapsing-


62

1996 HTA Canadian Coordinating Office for Health Technology

Assessment (CCOHTA)

Interferon beta

1-b and multiple

sclerosis -

summary [Preview]

63 1996 HTA Health Council of the

Netherlands/Gezondheidsraad

(GR)

Interferon-beta-

1b in patients

with multiple

sclerosis [Preview]

23


Assessment programme Cannabinoids

(cannabis

derivatives) for

treatment of the

symptoms of

multiple

sclerosis [Preview]

65 HTA Catalan Agency for Health

Information, Assessment and

Quality (CAHIAQ -formerly

CAHTA)

Clinical practice

guideline on

multiple

sclerosis [Preview]


Assessment programme Fingolimod for

relapsing or

remitting

multiple

sclerosis [Preview]


Assessment programme Natalizumab for

multiple

sclerosis [Preview]

Cochrane Database

Søgt på: ”multiple sclerosis”[MESH] and (rehabilitation or "daily living" or physiotherapy or "physical therapy" or "occupational therapy" or functioning):ti,ab,kw 16 fund

option1

24

Occupational therapy for multiple sclerosis

Esther EMJ Steultjens , Joost J Dekker , Lex M Bouter , Mieke M Cardol , Els

CHM Van den Ende and Jos van de Nes

January 2009

1. Review

option2

Whole‐ body vibration training for patients with neurodegenerative disease

Mercè Sitjà Rabert , David Rigau Comas , Azahara Fort Vanmeerhaeghe ,

Carme Santoyo Medina , Marta Roqué i Figuls , Daniel Romero‐Rodríguez and

Xavier Bonfill Cosp

February 2012

1. Review

option3

Memory Rehabilitation for people with multiple sclerosis

Roshan das Nair , Heather Ferguson , Daniel L Stark and Nadina B Lincoln

March 2012

1. Review

option4

Neuropsychological rehabilitation for multiple sclerosis

Eija M Rosti‐Otajärvi and Päivi I Hämäläinen

November 2011

1. Review

option5

Psychological interventions for multiple sclerosis

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003608/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009097.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008754.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009131.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004431.pub2/abstract

25

Peter W Thomas , Sarah Thomas , Charles Hillier , Kate Galvin and Roger Baker

January 2009

1. Review

option6

Multidisciplinary rehabilitation for adults with multiple sclerosis

Fary Khan , Lynne Turner‐Stokes , Louisa Ng , Trevor Kilpatrick and Bhasker

Amatya

December 2011

1. Ns 2. Review

option7

Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis

Fary Khan , Louisa Ng and Lynne Turner‐Stokes

December 2011

1. Ns 2. Review

option8

Exercise therapy for multiple sclerosis

Marc B Rietberg , Dina Brooks , Bernard MJ Uitdehaag and Gert Kwakkel

January 2011

1. Review

option9

Interventions for fatigue and weight loss in adults with advanced progressive illness

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006036.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007256.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007256.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003980.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008427.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008427.pub2/abstract

26

Cathy Payne , Philip J Wiffen and Suzanne Martin

August 2012

1. Review

option10

Treatment for ataxia in multiple sclerosis

Roger J Mills , Leesien Yap and Carolyn A Young

January 2009

1. Review

option11

Amantadine for fatigue in multiple sclerosis

Eugenio Pucci , Pedro Brañas Tato , Roberto D'Amico , Giorgio Giuliani ,

Alessandra Solari and Cristiana Taus

January 2009

1. Review

option12

Non pharmacological interventions for spasticity in multiple sclerosis

Bhasker Amatya , Fary Khan , Loredana La Mantia , Marina Demetrios and

Derick T Wade

February 2013

1. Review

option13

Aminopyridines for symptomatic treatment in multiple sclerosis

Alessandra Solari , Bernard MJ Uitdehaag , Giorgio Giuliani , Eugenio Pucci and

Cristiana Taus

January 2009

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005029.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002818.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009974.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001330/abstract

27

1. Review

option14

Anti‐ spasticity agents for multiple sclerosis

David Shakespeare , Mike Boggild and Carolyn A Young

January 2009

1. Review

option15

Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis

Yousheng Xiao , Jin Wang and Hongye Luo

April 2012

1. Review

option16

Interferon beta for secondary progressive multiple sclerosis

Loredana La Mantia , Laura Vacchi , Carlo Di Pietrantonj , George Ebers , Marco

Rovaris , Sten Fredrikson and Graziella Filippini

January 2012

1. Review

SBU (Sverige)

Søgt på: multiple sclerosis / Multipel skleros

0 fund

Socialstyrelsen (Sverige)

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001332/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009427.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005181.pub3/abstract

28

Søgt på: multiple sclerosis / Multipel skleros

3 fund

1. Rehabilitering vid kroniska neurologiska sjukdomar Datum: 2012-12-03 Visa med sökorden markerade Titel: - Rehabilitering vid kroniska neurologiska sjukdomar - Startdatum: - 2013-09-09 ...

vid kroniska neurologiska sjukdomar: Multipel skleros, Parkinsons sjukdom, postpolio,

neuromuskulära ... neurologiska sjukdomar. - Dag 1, em: Multipel skleros - Dag 2, fm:

Parkinsons sjukdom ...

Sökväg:

Start / SK-kurser / Rehabilitering vid kroniska ne...

2. Centrala rekommendationer i

demensriktlinjerna

Share on facebookShare on twitterShare on emailShare on print

Skriv ut

Här hittar du centrala rekommendationer som kan komma att påverka praxis och påverka

resursfördelningen inom vård och omsorg vid demenssjukdom.

Syftet med rekommendationerna är ge vägledning för beslut om resursfördelning på

gruppnivå.

Välj det område du vill läsa mer om

Att förebygga demenssjukdom

Utredning o Utredning och diagnostik

o Tidig social utredning och regelbunden strukturerad uppföljning

Organisation o Multiprofessionellt teambaserat arbete

o Utbildning av personal

Aktiviteter, fysisk träning och hjälpmedel Dagverksamhet Flytt och särskilt boende Stöd till anhöriga

Omvårdnad o Personcentrerad omvårdnad

http://www.socialstyrelsen.se/sk-kurser/rehabiliteringvidkroniskaneurohttp://www.socialstyrelsen.se/_layouts/Precio/SiteSeeker/ShowCache.aspx?resid=82423444&q=Multipel+skleros&il=sv&hitnr=2&url=http%3a%2f%2fwww.socialstyrelsen.se%2fsk-kurser%2frehabiliteringvidkroniskaneuro&uaid=16ABBB754F9623A2C8E39577D96BC389%253http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/javascript:window.print();javascript:window.print();http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/forebyggahttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/utredninghttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/organisationhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/aktiviteterhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/dagverksamhethttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/boendehttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/anhorigahttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/omvardnad

29

o Rekommendationer för professionen

o Pallitativ vård i livets slutskede

Läkemedelsbehandling Beteendemässiga- och psykiska symtom vid demenssjukdom och konfusion

3. Sök i demensriktlinjerna

Share on facebookShare on twitterShare on emailShare on print

Skriv ut

Här kan du söka i Nationella riktlinjer för vård och omsorg vid demenssjukdom. Sök i

fritextrutan, med hjälp av filtreringsalternativen till vänster eller sortera i listan nedan.

Nedan kan du också ladda ner samtliga rekommendationer i tillstånds- och åtgärdslistan

och det vetenskapliga underlaget.

Tillstånds- och åtgärdslista

Vetenskapligt underlag

Tillstånd Åtgärd Rekommendation

Anhöriga till personer med demenssjukdom

Psykosociala stödprogram 2


Kombinationsprogram 3


Avlösning 2


Psykosocialt stöd på distans 6

Anhöriga till yngre personer med demenssjukdom

Specifikt anpassat stöd 3

Anhöriga till yngre personer med demenssjukdom

Individuellt anpassad avlösning 3

Beteendemässiga och psykiska symtom vid Alzheimers sjukdom

Behandling med antiepileptika

(karbamazepin, valproat, topiramat) Icke-göra

Friska personer Mentalt och socialt stimulerande aktiviteter på fritiden för att

förebygga demenssjukdom

3

Friska personer Fysisk aktivitet för att förebygga demenssjukdom

3

http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/lakemedelhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/bpsdhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/javascript:window.print();javascript:window.print();http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/Documents/nr-demens-tillstandsochatgardslista.xlshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/Documents/nr-demens-tillstandsochatgardslista.xlshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/Documents/nr-demens-vetenskapligtunderlag.pdfhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/Documents/nr-demens-vetenskapligtunderlag.pdfjavascript:knowledgeDatabaseSearch('tillstand',%20'sort|UP')javascript:knowledgeDatabaseSearch('atgard',%20'sort|UP')javascript:knowledgeDatabaseSearch('rekommendation',%20'sort|UP')http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemensshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemensshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillyngrepersonermeddehttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillyngrepersonermeddehttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillyngrepersonermedde1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillyngrepersonermedde1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/beteendemassiga-ochpsykiskasymhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/beteendemassiga-ochpsykiskasymhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/friskapersonerhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/friskapersoner1

30


Friska personer Testning av riskgenen ApoE4 Icke-göra

Friska personer i medelåldern Behandling av högt blodtryck för att förebygga demenssjukdom

3

Kvinnor med måttlig till svår demensjukdom och urininkontinens

Bäckenbottenträning Icke-göra

Närstående till personer med demenssjukdom

Utbildningsprogram 2

Personer med agitation, aggressivitet eller vanföreställningar (hallucinationer) vid måttlig till...

Behandling med antipsykosmedel

(haloperidol) 8



(risperidon) 7



(olanzapin) 9

Personer med Alzheimers sjukdom Regelbunden, minst årlig, bedömning av behandlingslängd och

utsättningsförsök vid behandling

med...

1

Personer med Alzheimers sjukdom i särskilt boende

Kombinerad träning -

individanpassad, funktionell träning

med medelhög intensitet

5

Personer med Alzheimers sjukdom i särskilt boende

Individanpassade

träningspromenader 7

Personer med Alzheimers sjukdom och Downs syndrom

Behandling med

kolinesterashämmare 2

Personer med beteendemässiga och psykiska symtom vid Alzheimers sjukdom

Behandling med

kolinesterashämmare (donepezil,

galantamin, rivastagmin)

10

Personer med beteendemässiga och psykiska symtom vid Alzheimers sjukdom

Behandling med memantin 6

Personer med beteendemässiga och psykiska symtom vid demenssjukdom

Utredning och behandling av

bakomliggande orsaker 1

Personer med beteendemässiga och psykiska symtom vid demenssjukdom

Behandling till natten med

klometiazol 8

Personer med beteendemässiga Behandling med antipsykosmedel Icke-göra

javascript:knowledgeDatabaseSearch('tillstand',%20'sort|UP')javascript:knowledgeDatabaseSearch('atgard',%20'sort|UP')javascript:knowledgeDatabaseSearch('rekommendation',%20'sort|UP')http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/friskapersoner2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/friskapersonerimedelaldernhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/kvinnormedmattligtillsvardemenhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/kvinnormedmattligtillsvardemenhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/narstaendetillpersonermeddemenhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/narstaendetillpersonermeddemenhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivihttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivihttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivihttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivihttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomishttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomishttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomis1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomis1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomochttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomochttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-ochhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-ochhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-ochhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbpsdvidmattlig-svar

31


och psykiska symtom vid måttlig till svår demenssjukdom

(quetiapin)

Personer med demenssjukdom Tidig social utredning 1

Personer med demenssjukdom Årlig medicinsk och social uppföljning

1

Personer med demenssjukdom Personcentrerad omvårdnad 1

Personer med demenssjukdom Utbildning av personal för att förebygga och upptäcka vanvård

1

Personer med demenssjukdom Reminiscence 8

Personer med demenssjukdom Validation 8

Personer med demenssjukdom Multiprofessionellt teambaserat arbete inom vård och omsorg

2

Personer med demenssjukdom Utbildning av personal i vård, omvårdnad och omsorg

6

Personer med demenssjukdom Långsiktig personalutbildning som är kombinerad med praktisk träning,

handledning och feedback

1

Personer med demenssjukdom Handledning i kombination med utbildning till personal

3

Personer med demenssjukdom Behandling med omega-3-fettsyror FoU

Personer med demenssjukdom Behandling med vitamin E eller vitamin C

FoU

Personer med demenssjukdom i livets slutskede

Palliativ vård 1

Personer med demenssjukdom i särskilt boende

Multifaktoriell intervention (flera

samtidiga åtgärder) för att förebygga

fall

1

Personer med demenssjukdom i särskilt boende

Kombinerad träning -

individanpassad, funktionell träning

med medelhög till hög intensitet

5

Personer med demenssjukdom i särskilt boende och på sjukhus

Översyn av läkemedel för att

förebygga fall 1

Personer med demenssjukdom inom särskilt boende

Personligt utformade, berikade och

hemlika fysiska boendemiljöer 1

Personer med demenssjukdom och aggressivitet

Beteendetekniker 10


Validation 10


Fysisk aktivitet 5

Personer med demenssjukdom och Personal som kommunicerar på 2

javascript:knowledgeDatabaseSearch('tillstand',%20'sort|UP')javascript:knowledgeDatabaseSearch('atgard',%20'sort|UP')javascript:knowledgeDatabaseSearch('rekommendation',%20'sort|UP')http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbpsdvidmattlig-svarhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbpsdvidmattlig-svarhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom4http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom5http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom6http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom7http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom8http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom9http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom10http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom11http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomilivethttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomilivethttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarskhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarskhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarsk2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarsk2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarsk1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarsk1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdominomsahttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdominomsahttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagghttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagghttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagg1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagg1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagg2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagg2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochann

32


annan etnisk bakgrund samma modersmål med kulturkompetens

Personer med demenssjukdom och fysiska begränsningsåtgärder

Kontinuerliga observationer och

utvärderingar 1

Personer med demenssjukdom och fysiska begränsningsåtgärder

Utbildning och handledning av

personal för att minska användandet

av fysiska begränsningsåtgärder

1

Personer med demenssjukdom och förstoppning

Magmassage 8

Personer med demenssjukdom och förstoppning eller risk för förstoppning

Behandling med paraffinolja Icke-göra


Biofeedback (träning av

muskelkoordination) Icke-göra


Regelbundna toalettvanor 1

Personer med demenssjukdom och konfusion

Läkemedelsbehandling med

antipsykosmedel (haloperidol,

risperidon)

8


Läkemedelsbehandling med

olanzapin Icke-göra


Aktivering dagtid med tillägg av

klometiazol nattetid 8

Personer med demenssjukdom och misstänkt konfusion

Utredning och behandling av

bakomliggande orsaker 1

Personer med demenssjukdom och risk för förstoppning

Fiberrik kost och ett adekvat

vätskeintag genom tillförsel av

vätska

1

Personer med demenssjukdom och risk för förstoppning

Fysisk aktivitet 1

Personer med demenssjukdom och risk för nedsatt munhälsa

Strukturerad bedömning av

munhälsa 1

Personer med demenssjukdom och skrikbeteende

Beteendetekniker 10

Personer med demenssjukdom och undernäring

Nutritionsintervention -

energiberikning av mat och dryck,

extra mellanmål,

konsistensanpassning

1

Personer med demenssjukdom och undernäring

Nutritionsintervention i form av

tillägg av näringsdrycker 5

javascript:knowledgeDatabaseSearch('tillstand',%20'sort|UP')javascript:knowledgeDatabaseSearch('atgard',%20'sort|UP')javascript:knowledgeDatabaseSearch('rekommendation',%20'sort|UP')http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochannhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfyshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfyshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfys1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfys1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochforhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochforhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochforhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkonhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkonhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkon1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkon1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkon2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkon2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personerme